Safety and immunogenicity of a heterologous prime-bosst vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults, children and infants in a malaria endemic area

Oxford University, Jenner Institute0 个研究点目标入组 52 人开始时间: 2010年6月15日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Any of the following constitute an exclusion criterion:
•¿Clinically significant history of skin disorder (psoriasis, contact dermatitis etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
•¿History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon.
•¿History of splenectomy.
•¿Haemoglobin less than 9.0 g/dL
•¿Serum creatinine concentration above >130mmol/L
•¿Serum ALT concentration >69 IU/L
•¿Blood transfusion within one month ofenrolment. .
•¿History of vaccination with previous experimental malaria vaccines.
•¿Administration of any other vaccine or immunoglobulin within two weeks before vaccination.
•¿Current participation in another clinical trial, or within 12 weeks of this study.
•¿Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.
•¿Likelihood of travel away from the study area.
•¿HIV positive.

发起方

Oxford University, Jenner Institute